Evidence map›Paper›PMID 36733313›Full record

ArticlePulmonary circulation2023

Oral Liushen pill for patients with COVID-19: A prospective randomized controlled trial.

Jianping Zhang, Yian Liu, Wei Lei, Junheng Shen, Jing Lu, Tao Tao, Xu Cao, Zhong Yang, Jianan Huang, Cuilin Shi

Open access · goldAbstract read
In one paragraph

Article in Pulmonary circulation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jianping ZhangThe Fifth People's Hospital of Suzhou Suzhou China.
Yian LiuThe Fifth People's Hospital of Suzhou Suzhou China.
Wei LeiDepartment of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Soochow University Suzhou China.
Junheng ShenThe Fifth People's Hospital of Suzhou Suzhou China.
Jing LuThe Fifth People's Hospital of Suzhou Suzhou China.
Tao TaoThe Fifth People's Hospital of Suzhou Suzhou China.
Xu CaoThe Second Affiliated People's Hospital of Soochow University Suzhou China.
Zhong YangThe Fifth People's Hospital of Suzhou Suzhou China.
Jianan HuangDepartment of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Soochow University Suzhou China.
Cuilin ShiThe Fifth People's Hospital of Suzhou Suzhou China.ORCID 0000-0002-9394-7177
The Fifth People’s Hospital of Suzhou · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the efficacy and safety of Liushen pill combined with basic treatment for patients with COVID-19. In total, 181 patients hospitalized with COVID-19, classified as asymptomatic mild type, were randomly divided into the experimental (

Indexed as

clinical trialsCOVID‐19 infectionLiushen pilltraditional Chinese medicine (TCM)virus negative conversion

Identifiers

PMID36733313
PMCPMC9886519
OpenAlexW4313641395

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.